Replies to post #3933 on ImClone Systems Inc (formerly IMCL)

[DewDiligence]

>the humanized CDR-grafted approach that IMCL mentions in the patent would seem to be covered by PDLI's patents.<

Yes, that’s correct. The language in the IMCL patent application may be intentionally using verbatim language from one or more PDLI patents on the humanization process in order to assure that an EGFR mAb developed using PDLI’s technology is “fenced in” by IMCL’s patent.